【今回のトピックス】
ASCO annual meeting 2016: Collective Wisdom
今回のASCO開催直前号では、SynixとCerner Enviza℠が注目する演題をお届けいたします。
昨年の「Illumination & Innovation: Transforming Data into Learning」に対し、今年のテーマは「Collective Wisdom: The Future of Patient-Centered Care and Research」。
がん免疫療法の台頭と進化するPrecision Medicine、目覚ましい進展を続けるがん治療の現状を反映し、更なる集合知の形成を呼びかけるテーマのようです。
Abstract 6009 (Monday June 6, 11:30a.m. – 1:00p.m.)
Further evaluations of nivolumab (nivo) versus investigator’s choice (IC) chemotherapy for recurrent or metastatic (R/M) squamous cell carcinoma of the head and neck (SCCHN): CheckMate 141
Abstract 6010 (Monday June 6, 11:30a.m. – 1:00p.m.)
Biomarkers and response to pembrolizumab (pembro) in recurrent/metastatic head and neck squamous cell carcinoma (R/M HNSCC)
Abstract 6011 (Monday June 6, 11:30a.m. – 1:00p.m.)
Preliminary results from KEYNOTE-055: Pembrolizumab after platinum and cetuximab failure in head and neck squamous cell carcinoma (HNSCC)
Abstract 6012 (Monday June 6, 11:30a.m. – 1:00p.m.)
Efficacy and safety of pembrolizumab in recurrent/metastatic head and neck squamous cell carcinoma (R/M HNSCC): Pooled analyses after long-term follow-up in KEYNOTE-012
Abstract 9500 (Monday June 6, 1:15p.m. – 4:15p.m.)
Results of NEMO: A phase III trial of binimetinib (BINI) vs dacarbazine (DTIC) in NRAS-mutant cutaneous melanoma
Abstract 500 (Monday June 6, 1:15p.m. – 4:15p.m.)
Pathologic complete response (pCR) rates after neoadjuvant trastuzumab emtansine (T-DM1 [K]) + pertuzumab (P) vs docetaxel + carboplatin + trastuzumab + P (TCHP) treatment in patients with HER2-positive (HER2+) early breast cancer (EBC) (KRISTINE)
Abstract LBA4 (Sunday June 5, 1:00p.m. – 4:00p.m.)
Phase III randomized controlled study of daratumumab, bortezomib, and dexamethasone (DVd) versus bortezomib and dexamethasone (Vd) in patients (pts) with relapsed or refractory multiple myeloma (RRMM): CASTOR study
Abstract 7506 (Sunday June 5, 9:45a.m. – 12:45p.m.)
PILLAR-2: A randomized, double-blind, placebo-controlled, phase III study of adjuvant everolimus (EVE) in patients (pts) with poor-risk diffuse large B-cell lymphoma (DLBCL)
Abstract 7000 (Saturday June 4, 3:00p.m. – 6:00p.m.)
Final results of a phase III randomized trial of CPX-351 versus 7+3 in older patients with newly diagnosed high risk (secondary) AML
Abstract 5006 (Monday June 6, 8:00a.m. – 11:00a.m.)
Cabazitaxel vs docetaxel in chemotherapy-naive (CN) patients with metastatic castration-resistant prostate cancer (mCRPC): A three-arm phase III study (FIRSTANA)
Abstract 4018 (Saturday June 4, 3:00p.m. – 4:15p.m.)
TACE 2: A randomized placebo-controlled, double-blinded, phase III trial evaluating sorafenib in combination with transarterial chemoembolisation (TACE) in patients with unresectable hepatocellular carcinoma (HCC)
PD-1阻害剤のHead & Neckでの開発動向等、これからの追加適応には注目しつつ、免疫療法以外の分子標的薬等の結果にも注目をしております。
会期中にも、会場の様子と前半の講演ハイライトについてお届けできればと思います。
それでは、現地でも皆様とお会いできることを期待しております。
■ 編集後記 ■
第5回ニュースレターはいかがでしたでしょうか？
本ニュースレターで取り上げましたトピックについてなど、ご質問やご感想がございましたらご連絡頂けますと幸いです。